Publications by authors named "Steven DellaRocca"

Claim this Profile
D
Dual HDAC and PI3K Inhibitor CUDC-907 Downregulates MYC and Suppresses Growth of MYC-dependent Cancers.
Kaiming Sun, Ruzanna Atoyan, Mylissa A Borek, Steven Dellarocca, Maria Elena S Samson

Mol Cancer Ther· February 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cancer network disruption by a single molecule inhibitor targeting both histone deacetylase activity and phosphatidylinositol 3-kinase signaling.
Changgeng Qian, Cheng-Jung Lai, Rudi Bao, Da-Gong Wang, Jing Wang, Steven DellaRocca

Clin Cancer Res· August 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
CUDC-101, a multitargeted inhibitor of histone deacetylase, epidermal growth factor receptor, and human epidermal growth factor receptor 2, exerts potent anticancer activity.
Cheng-Jung Lai, Rudi Bao, Xu Tao, Jing Wang, Ruzanna Atoyan, Steven DellaRocca

Cancer Res· May 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Targeting heat shock protein 90 with CUDC-305 overcomes erlotinib resistance in non-small cell lung cancer.
Rudi Bao, Cheng-Jung Lai, Da-Gong Wang, Hui Qu, Ling Yin, Steven DellaRocca

Mol Cancer Ther· December 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
CUDC-305, a novel synthetic HSP90 inhibitor with unique pharmacologic properties for cancer therapy.
Rudi Bao, Cheng-Jung Lai, Hui Qu, Dagong Wang, Ling Yin, Steven DellaRocca

Clin Cancer Res· June 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis